A Study to Evaluate the Safety, Tolerance, and Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020

Phase 1 Completed 54 enrolled Otsuka Pharmaceutical Development & Commercialization, Inc.

RandomizedCrossoverOpen-labelOther

Summary

To investigate whether there is a food-effect with oral administration with EB-1020 as well as to obtain information on the safety, and tolerability of EB-1020 in a range of doses.

Timeline

Start: 2013-02-01
Primary completion: 2014-02-01
Completion: 2014-02-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Centanafadine	Small molecule	—	Oral

Indications

No indication recorded.